A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants
Completed · Phase 2 · NCT06086626
Conditions: Gram-Negative Bacterial Infections
At a glance
- Research payments reported, 2025
- $115,351
- U.S. investigators named
- 2
- Sites paid
- 3
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- Shionogi
- Tested
- Cefiderocol (drug), Standard of Care (drug)
- Dates
- Started 2024-03-14; completion 2025-03-31
- Results posted
- Not yet
The primary purpose of this study is to understand the pharmacokinetics (PK) of single and multiple doses of cefiderocol in children from birth to less than 3 months of age with suspected or confirmed aerobic Gram-negative bacterial infections.
From ClinicalTrials.gov, last updated 2026-03-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Shionogi Inc reported $115,351 in research payments for this study in 2025 (27 payments).
Products named: Fetroja
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Arkansas Childrens Research $59,315
- Sharp Memorial Hospital $35,066
- University of Arkansas Medical Sciences, AR $20,970
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.